Merlin Capital’s Intellia Therapeutics NTLA Stock Holding History

Merlin Capital’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$488K	Sell	17,724 -9,110	-34%	-$253K	1.45%	39
2023 Q4	$818K	Buy	26,834 +8,308	+45%	+$239K	2.62%	4
2023 Q3	$586K	Buy	18,526 +885	+5%	+$34.3K	2.19%	19
2023 Q2	$719K	Buy	17,641 +5,031	+40%	+$204K	2.43%	11
2023 Q1	$470K	Buy	12,610 +307	+2%	+$12K	1.7%	33
2022 Q4	$429K	Buy	12,303 +646	+6%	+$30.7K	1.06%	46
2022 Q3	$652K	Sell	11,657 -517	-4%	-$32.1K	1.51%	19
2022 Q2	$630K	Buy	12,174 +599	+5%	+$30.4K	1.26%	25
2022 Q1	$841K	Buy	11,575 +5,020	+77%	+$425K	1.11%	22
2021 Q4	$775K	Buy	+6,555	New	+$821K	0.9%	38

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Merlin Capital's NTLA Position: Q1 2024 in Review

Merlin Capital reduced its Intellia Therapeutics (NTLA) stake by 34% in Q1 2024, selling an estimated $253K and leaving 17,724 shares worth $488K. The position accounts for 1.45% of the portfolio, ranked #39.

Merlin Capital first reported a position in NTLA in Q4 2021 and has held it in 10 quarters since. The position peaked at $841K in Q1 2022. 284 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

Merlin Capital held 17,724 shares of Intellia Therapeutics worth $488K as of Q1 2024.
Merlin Capital sold 9,110 Intellia Therapeutics shares in Q1 2024, an estimated $253K.
Intellia Therapeutics made up 1.45% of Merlin Capital's portfolio in Q1 2024, its #39 holding.
Merlin Capital first reported a position in Intellia Therapeutics in Q4 2021 and has held it in 10 quarters since.
Merlin Capital's Intellia Therapeutics position peaked at $841K in Q1 2022.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Merlin Capital's 13F filing for Q1 2024, filed 13 May 2024.